PharmaEssentia Seeks Brazil Approval for BESREMi in Essential Thrombocythemia

MT Newswires Live11-19 13:38

PharmaEssentia (TPE:6446) has submitted an application to Brazil's Health Regulatory Agency (ANVISA) to add essential thrombocythemia (ET) as a new indication for its drug BESREMi (ropeginterferon alfa-2b), according to a Wednesday filing to the Taiwan Stock Exchange.

The company's shares were down over 3% in recent trade.

The post-marketing variation application seeks approval for treating adults with ET, a rare blood disorder characterized by excessive platelet production.

ANVISA's review period is 60 days for priority applications and 180 days for ordinary applications, excluding requests for additional information

BESREMi was approved in Brazil in March 2025 for treating adults with polycythemia vera. It is already approved for ET in several markets, including the US, Japan, and China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment